PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 487/04, A61K 31/505 // (C07D 487/04, 239:00, 209:00)

A1

(11) International Publication Number: WO 98/41525

(43) International Publication Date: 24 September 1998 (24.09.98)

(21) International Application Number: PCT/EP98/01357

(22) International Filing Date: 9 March 1998 (09.03.98)

(30) Priority Data:
60/040,836 19 March 1997 (19.03.97) US

(71) Applicant *(for all designated States except US)*: KNOLL AKTIENGESELLSCHAFT [DE/DE]; Knollstrasse, D–67061 Ludwigshafen (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CALDERWOOD, David, John [GB/GB]; R5 Pennyfoot Street, Nottingham NG1 1GF (GB). JOHNSTON, David, Norman [GB/GB]; R5 Pennyfoot Street, Nottingham NG1 1GF (GB). RAFFERTY, Paul [GB/GB]; R5 Pennyfoot Street, Nottingham NG1 1GF (GB). TWIGGER, Helen, Louise [GB/GB]; R5 Pennyfoot Street, Nottingham NG1 1GF (GB). MUNSCHAUER, Rainer [DE/US]; 46 Hunting Avenue, Shrewsbury, MA 01545 (US). ARNOLD, Lee [CA/US]; 216 Ruggles Street, Westborough, MA 01581 (US).


(74) Agents: MILLER, Thomas, Kerr et al.; BASF Aktiengesellschaft, D–67056 Ludwigshafen (DE).

(81) Designated States: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PYRROLO[2,3D]PYRIMIDINES AND THEIR USE AS TYROSINE KINASE INHIBITORS

(57) Abstract



(I)



(a)

Compounds of formula (I) including pharmaceutically acceptable salts thereof in which R_1 represents hydrogen, 2–phenyl–1,3–dioxan–5–yl, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, a C_{5-7} cycloalkenyl group or an (optionally substituted phenyl) C_{1-6} alkyl group wherein the alkyl, cycloalkyl and cycloalkenyl groups are optionally substitued by one or more groups of the formula OR_A in which R_A represents H or a C_{1-6} alkyl group provided that a group of the formula OR_A is not located on the carbon attached to nitrogen; R_2 represents hydrogen, a C_{1-6} alkyl group, a C_{3-8} cycloalkyl group, halo, hydroxy, an (optionally substituted phenyl) C_{1-6} alkyl group, optionally substituted phenyl or R_4; and R_3 represents a group of formula (a) in which the phenyl ring is additionally optionally substituted and A represents NH, O, $NHSO_2$, SO_2NH, a C_{1-4} alkylene chain, NHCO, $NHCO_2$, CONH, NHCONH, CO_2 or $S(O)_p$ in which p is 0, 1 or 2, or A is absent and R_5 is attached directly to the phenyl ring; and R_5 represents optionally substituted phenyl and, additionally, when A is absent R_5 represents a) a phthalimido group optionally substituted by halo or b) a pyrazolylamino group in which the pyrazole ring is optionally substituted by one or more of the following: hydroxy or optionally substituted phenyl; R_4 represents a heterocyclic group; are described which are useful in treating proliferative diseases and disorders of the immune system in mammals. Processes to prepare these compounds and pharmaceutical compositions containing these compounds are also described.